Drugs / rmhTNF-NC
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07397819 | Nov 2025 → Jun 2028 expected | peritoneal neoplasm | Dong sheng Zhang | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07196540 | Sep 2025 → Dec 2028 expected | digestive system neoplasm | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06433869 | Dec 2023 → Dec 2026 expected | peritoneal neoplasm | Sun Yat-sen University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rmhTNF-NC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07196540 ↗ |
| Known as | Recombinant Mutant Human Tumor Necrosis Factor | “intraperitoneal injection of Recombinant Mutant Human Tumor Necrosis Factor (rmhTNF-NC) and tislelizumab” NCT07196540 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Tumor Necrosis Factor” NCT06433869 ↗ |
| Route | Other | “local intraperitoneal injection of PD-1 inhibitor, rmhTNF-NC and bevacizumab” NCT06433869 ↗ |